Core Viewpoint - Rosen Law Firm is reminding investors who purchased Petco Health and Wellness Company, Inc. securities between January 14, 2021, and June 5, 2025, of the upcoming lead plaintiff deadline on August 29, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Petco securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Petco made false and misleading statements regarding the sustainability of its pandemic-related growth and the viability of its business model focused on premium pet food [5]. - It is claimed that the strength of Petco's product strategy was overstated, and the company downplayed the severity of issues affecting its business [5]. - The lawsuit asserts that these misrepresentations led to investor damages when the true situation was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lockheed Martin securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Lockheed Martin securities between January 23, 2024, and July 21, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 26, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Lockheed Martin - The lawsuit alleges that Lockheed Martin made false and misleading statements regarding its internal controls and risk management related to contracts [5]. - Specific claims include the lack of effective internal controls, inaccurate reviews of program requirements, and overstated capabilities in delivering contract commitments [5]. - As a result of these alleged misrepresentations, the lawsuit claims that investors suffered damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the upcoming lead plaintiff deadline on October 10, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased SelectQuote securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements, including directing Medicare beneficiaries to plans that compensated SelectQuote rather than providing unbiased comparisons [4]. - It is claimed that SelectQuote received illegal kickbacks to steer beneficiaries to certain insurers and limit enrollment in competitors' plans, violating applicable laws and regulations [4]. - The lawsuit asserts that the misleading statements about SelectQuote's business operations led to investor damages when the true details became public [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 15, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, while concealing adverse facts about its safety and efficacy data from a Phase 2 trial [5] - These misleading statements allegedly led to shareholders purchasing securities at artificially inflated prices, resulting in damages when the true information became public [5]

Core Viewpoint - A class action lawsuit has been filed against Altimmune Inc. by Berger Montague on behalf of investors who acquired the company's securities during the specified class period from August 10, 2023, to June 25, 2025 [1][2]. Company Overview - Altimmune Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [2]. Legal Action Details - Investors who purchased Altimmune securities during the class period have until October 6, 2025, to seek appointment as lead plaintiff representatives [2]. - The lawsuit follows a press release from Altimmune on June 26, 2025, announcing disappointing results from its IMPACT Phase 2b trial of Pemvidutide for MASH treatment, where the primary endpoint of fibrosis reduction did not achieve statistical significance [3]. Stock Price Impact - Following the announcement of the trial results, Altimmune's stock price plummeted by 53.2% in one day, dropping from a closing price of $7.71 on June 25, 2025, to $3.61 on June 26, 2025 [4].

Core Viewpoint - Berger Montague PC is investigating claims against Novo Nordisk A/S following a class action lawsuit related to the company's lowered sales and profit guidance for the second half of fiscal 2025 [1][3]. Company Summary - Novo Nordisk A/S, a global pharmaceutical company based in Denmark, has faced a significant stock price decline after announcing a reduction in sales and profit expectations due to various market challenges [1][3]. - The company cited persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® as reasons for the guidance cut [3]. Stock Performance - Following the announcement on July 29, 2025, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Investor Information - Investors who purchased Novo securities between May 7, 2025, and July 28, 2025, have until September 30, 2025, to seek appointment as lead plaintiff representative in the class action [2].

Group 1 - A class action lawsuit has been filed against KinderCare Learning Companies, Inc. on behalf of investors who purchased shares during the period from October 6, 2024, to August 12, 2025, including its October 2024 IPO [1][2] - The lawsuit alleges that the IPO registration statement contained false and misleading statements, failing to disclose incidents of child abuse, neglect, and harm at KinderCare facilities, and that the company did not meet minimum care standards [3] - Since the IPO, KinderCare's shares have significantly declined, reaching lows near $9 per share, resulting in substantial losses for investors [4] Group 2 - Investors who acquired KinderCare securities during the class period have until October 14, 2025, to seek appointment as lead plaintiff representative of the class [2] - Berger Montague, the law firm representing the plaintiffs, has a long history in securities class action litigation, having represented investors for over five decades [5]

Core Points - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities between October 9, 2024, and July 10, 2025, of the lead plaintiff deadline on September 15, 2025 [1] - Investors may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [2] - A class action lawsuit has been filed, and interested parties can join by contacting the firm or visiting their website [3] Case Details - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [5] - Defendants allegedly made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from the Phase 2 HOPE-2 trial [5] - The misleading information is claimed to have caused shareholders to purchase securities at inflated prices, leading to damages when the truth was revealed [5] Rosen Law Firm's Credentials - The firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has recovered hundreds of millions for investors [4] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [4]

Group 1 - A class action lawsuit has been filed against Altimmune Inc. on behalf of investors who acquired its securities between August 10, 2023, and June 25, 2025 [1][2] - The lawsuit follows the announcement of disappointing results from the IMPACT Phase 2b trial of Pemvidutide for treating MASH, where the primary endpoint of fibrosis reduction did not achieve statistical significance [3] - Following the trial results announcement, Altimmune's stock price plummeted by 53.2%, closing at $3.61 on June 26, 2025, down from $7.71 the previous day [4] Group 2 - Altimmune is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH [2] - The company had previously made positive statements regarding the trial results, which ultimately did not materialize as expected [3]

Group 1 - A class action lawsuit has been filed against Sable Offshore Corp. by Berger Montague PC on behalf of investors who acquired Sable's publicly traded securities between May 19, 2025, and June 3, 2025 [1][2] - The lawsuit alleges that Sable made materially false and misleading statements regarding the status of its oil production, specifically claiming that production had restarted off the coast of California when it had not [3] - These misrepresentations are said to have artificially inflated Sable's stock price, leading to investor harm when the truth was revealed [3] Group 2 - Investors who purchased Sable securities during the class period have until September 26, 2025, to seek appointment as lead plaintiff representative [2] - Berger Montague has a long history in securities class action litigation, having represented individual and institutional investors for over five decades [4]